The last week of August proved to be a relatively significant one for multiple med-tech companies. Although the Labor Day holiday is likely to keep a lid on the news flow in the first week of September, there are a few upcoming earnings reports. What's more, the timing of restructurings, acquisitions and the like are inherently unpredictable and I would not be surprised to hear more news along these lines.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Helicos Looks Like It's Out of Moves
Few readers are going to be familiar with Helicos BioSciences (OTC:HLCS), as this tiny life sciences company has failed to successfully commercialize its direct DNA and RNA molecule sequencing technology. Although the technology is legitimately interesting, the company's execution mistakes left it with basically a long-shot survival strategy - suing other, larger, life science companies like Pacific Biosciences (Nasdaq:PACB), Life Technologies (Nasdaq:LIFE) and Illumina (Nasdaq:ILMN) for patent infringement.

Unfortunately for Helicos shareholders, the company may well have just lost the last hand in the game. The company dropped its litigation with Life Tech and settled with PacBio in May, but there has been nothing in Helicos' SEC filings to suggest that the settlement was financially meaningful. Worse still, the company saw a judge render a summary judgment invalidating the remaining patent in question against Illumina. At this point, the best remaining hope for Helicos is that a larger life sciences company is willing to pay something for its IP and technology, but investors should not expect to see any significant benefit from such an outcome.

SEE: Investing In The Healthcare Sector

Two More Companies Hope to Find Better Margins Through Restructuring
Two out of the three players in the North American cardiac rhythm management market (that is pacemakers and ICDs) have apparently launched restructurings. The news that Boston Scientific (NYSE:BSX) is doing so again scarcely qualifies as news, as this company has been in seemingly perpetual restructuring/turnaround for years. Nevertheless, the company will apparently still cut more jobs and separate its two main cardiovascular businesses (after combining them a while back).

The news of a restructuring at St. Jude Medical (NYSE:STJ) is a little more surprising, as this company has been doing relatively better despite a weak CRM market. St. Jude will reportedly be firing 300 people and reorganizing its business into two operating units focused on implantable electronic devices and cardiovascular/ablation technology.

SEE: Cashing In On Corporate Restructuring

AstraZeneca Makes a Good Hire
AstraZeneca
(NYSE:AZN) has been a struggling Big Pharma for some time now, as patent expirations and pipeline failures have left the company's revenue situation in poor shape. In recent months the company has been an active acquirer and partner - tying up with Amgen (Nasdaq:AMGN), buying Ardea and sharing in Bristol-Myers' (NYSE:BMY) purchase of Amylin.

Now the company has a new leader as well. AstraZeneca has tapped Pascal Soriot as the new CEO. Soriot is the former CEO of Genentech and has served as Roche's (OTC:RHHBY) Chief Operating Officer of the pharmaceutical division since the acquisition of Genentech. This is an excellent hire for AstraZeneca, given Soriot's demonstrated ability in overseeing successful pipeline development and product launches for many years now. While this is a loss for Roche, it's not altogether unexpected and the company has a deep bench of managerial talent.

SEE: 6 Great Companies With Top-Notch Healthcare Benefits

The Bottom Line
Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally. For what it's worth, it's not uncommon for healthcare stocks to "drift" in the late summer. The Health Care Select Sector SPDR (ARCA:XLV) is up about 12% year-to-date, below the the 12.8% return of the S&P 500. The iShares Dow Jones US Pharmaceuticals ETF (ARCA:IHE) is up about 14%, while the iShares Dow Jones US Medical Devices ETF (ARCA:IHI) is up almost 12%. The SPDR Biotech ETF (ARCA:XBI) continues its tear, having risen almost 35% year-to-date.

At the time of writing, Stephen D. Simpson owned shares of Roche, and has since 2011.

Related Articles
  1. Economics

    India: Why it Might Pay to Be Bullish Right Now

    Many investors are bullish on India for all the right reasons. Does it present an investing opportunity?
  2. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  3. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  4. Investing Basics

    Building My Portfolio with BlackRock ETFs and Mutual Funds (ITOT, IXUS)

    Find out how to construct the ideal investment portfolio utilizing BlackRock's tools, resources and its popular low-cost exchange-traded funds (ETFs).
  5. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  6. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  7. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  8. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  9. Investing

    3 Things About International Investing and Currency

    As world monetary policy continues to diverge rocking bottom on interest rates while the Fed raises them, expect currencies to continue their bumpy ride.
  10. Stock Analysis

    The Top 5 Micro Cap Alternative Energy Stocks for 2016 (AMSC, SLTD)

    Follow a cautious approach when purchasing micro-cap stocks in the alternative energy sector. Learn about five alternative energy micro-caps worth considering.
RELATED FAQS
  1. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  2. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  3. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  4. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  5. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
  6. What is the formula for calculating earnings per share (EPS)?

    Earnings per share (EPS) is the portion of a company’s profit that is allocated to each outstanding share of common stock, ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center